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ABSTRACT
The Effects of β-Amyloid on α7 Nicotinic Acetylcholine Receptors
Expressed in Xenopus Oocytes
Malia L. Anderson
Department of Physiology and Developmental Biology, BYU
Masters of Science
The exact mechanism and progression of Alzheimer’s disease (AD) at present is not fully
understood. In patients suffering from AD, damage to the hippocampal region and impairment of
learning and memory is present. It is also known that a buildup of β-amyloid plaques occur in
AD patients and that β-amyloid interacts with some subtypes of neuronal nicotinic acetylcholine
receptors (neuronal nAChRs). These receptors are composed of five subunits. The most
prevalent nAChR subunit composition through the brain as a whole is α7. Previous data
produced from our lab suggests that α7 nAChRs are also one of the most prevalent subunits
expressed by interneurons within the hippocampal region, a part of the brain known to be
involved in memory and learning. It is hypothesized that one mechanism through which learning
and memory becomes impaired in AD is through the interaction of β-amyloid with these
nAChRs. It has previously been established that nanomolar amounts of β-amyloid inhibit the
peak currents of α7 nAChRs. However, concentrations of β-amyloid in the picomolar range, in
some studies show an activation of α7 nAChRs, while other studies no activation is seen. In this
experiment we show that human α7 subunit nAChRs are not activated by β-amyloid42 at 1 pM30 nM concentrations. We also show that short, seven-second applications of β-amyloid interact
with the α7 nAChRs to alter the kinetics of the channel, however, the exact mechanism and
pattern by which it effects the channel is still unclear.
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INTRODUCTION
Alzheimer’s Disease
Alzheimer’s Disease (AD) is a form of dementia most prevalent in people over the age of 65
(Brookmeyer, Johnson, Ziegler-Graham, & Arrighi, 2007). It is a neurodegenerative disease that
leads to decreased cognitive performance, impaired memory, and eventually death (Waldemar et
al., 2007). The early stages are rather difficult to diagnose since the symptoms may be subtle or
indicative of other disorders. Clinical diagnoses are made from patient histories, cognitive tests,
and most recently, the use of advanced medical imaging of the brain (Dougall, Bruggink, &
Ebmeier, 2004; Jack et al., 2008). In 2006, there were over 26.6 million people diagnosed with
AD worldwide and it is predicted that by 2050, 1 in 85 people globally will be affected
(Brookmeyer et al., 2007). The course of AD is unique to each person making it difficult to
assess a prognosis for an individual. However, after diagnosis, the mean life expectancy is under
seven years with less than three percent of patients surviving more than fourteen years (Molsa,
Marttila, & Rinne, 1995). At present, AD is an incurable disease. While the exact mechanisms
of development and progression of the disease are currently not fully understood, two hallmarks
of AD include damage to the hippocampus and the accumulation of extracellular plaques that
contain amyloid proteins (Price, Davis, Morris, & White, 1991).
The hippocampus is located in the medial temporal lobe of the brain and is part of the
limbic system. It is known to play a role in learning and memory with acetylcholine being a
crucial neurotransmitter for signaling and proper function (Lynch, 2004). Cholinergic input in
the hippocampus is delivered via the septum-diagonal band complex which projects to many
regions of the hippocampus including the CA1 and CA3 (Frotscher & Leranth, 1985) and has as
one of its targets, nicotinic acetylcholine receptors (nAChRs) on hippocampal interneurons
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(Jones & Yakel, 1997). Thus, nAChRs in the hippocampus play a critical role in the ability to
form memories and in the learning process.

Acetylcholine Receptors
Acetylcholine receptors (AChRs) are broken down into two subgroups; nicotinic AChRs,
or muscarinic AChRs (mAChRs), depending on whether nicotine or muscarine can activate the
channels in addition to other ligands. NAChRs can be further broken down to either muscle or
neuronal nAChRs. Neuronal nAChRs are widely distributed throughout the brain and the
peripheral nervous system, and can be found both pre and post synaptically, forming ligandgated ion channels which increase the permeability of the membrane to cations (Albuquerque,
Pereira, Alkondon, & Rogers, 2009).
Each nAChRs is composed of five subunits that form either a homopentamer or
heteropentamer ion channel. To date, 17 subunit genes have been identified: 5 of which are
classified as muscle-type, 12 are neuronal-type, and only 9 subunits are expressed in the human
genome with the remaining subunits being found in the genomes of chicks and rats (Le Novere
& Changeux, 1995). The subunits identified thus far for neuronal nicotinic AChRs are: α2
through α10 and β2 through β4 (Albuquerque et al., 2009); with α7, α8, and α9, being the only
subunits that can form homopentamer channels (Karlin, 2002). The varying subunit
compositions create channels that display different kinetics and ligand binding properties. Thus,
a specific agonist or antagonist for one subunit composition will not interact with all subunit
configurations in the same manner (Sala et al., 2005).
Overall, the most abundant homopentamer subunit configuration present in the brain is
α7 (Figure 1). A high concentration of these subunits is located in the hippocampus, a region
4

known to play an important role in learning and memory. (Flores, Rogers, Pabreza, Wolfe, &
Kellar, 1992; Gopalakrishnan et al., 1996).

Figure 1 A homopentameter nAChR composed of five α7 subunits.
The subunits assemble together forming a channel where
calcium and other positive ions can pass through.
The hippocampal region of AD patients have consistently shown significant losses in
radioligand binding sites corresponding to neuronal nicotinic acetylcholine receptors (nAChRs),
implicating a correlation between AD and nAChRs (Nordberg, 2001). In addition to binding
ACh, these receptors are also able to interact with β-amyloid (Wang, Lee, Davis, & Shank,
2000).

β-amyloid
β-amyloid, the main constituent of the amyloid plaques present in AD patients, is a
transmembrane protein that is formed by several successive cleavages of the amyloid precursor
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protein (APP). Cleavage of APP by α-secretase disrupts the β-amyloid region, preventing the
release of β-amyloid. However, β-secretase cleavage followed by γ-secretase cleavage releases
the β-amyloid protein (Figure 2) (Kametani, 2008; Selkoe, 1998). This protein can be 36-43
amino acids long, with 40 or 42 being the most common isoforms.

Figure 2 β-amyloid, a transmembrane protein, is released when
APP is cleaved by β and γ-secretases. Cleavage of APP
by α-secretase prevents the release of β-amyloid.
β-amyloid40 is the main constituent of the β-amyloid population in normal individuals,
however, in AD the balance between β-amyloid40 and β-amyloid42 shifts so that β-amyloid42
becomes the most predominate form (Kuo et al., 1996; Schupf et al., 2010). The production of
β-amyloid is thought to follow a circadian rhythm, possibly explaining why early onset AD is
associated with chronic sleep deprivation (Kang et al., 2009). The estimated levels of
endogenously produced β-amyloid in healthy rodents are in the picomolar range (Cirrito et al.,
2003).
Along with being present in an increased amount in AD patients, β-amyloid42 has also
been shown to be toxic to neurons (Lambert et al., 1998). Furthermore, studies have shown that
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mice transgenically engineered to over express β-amyloid display symptoms similar to those
seen in AD (Hsiao et al., 1996; van Groen, Kiliaan, & Kadish, 2006). Under physiological
conditions, β-amyloid proteins have been found to aggregate. Three different forms of β-amyloid
have been identified: monomers, oligomers, and fibrils. These forms of β-amyloid display
differing degrees of cell toxicity (Dahlgren et al., 2002).
Originally, due to studies that showed solutions containing β-amyloid in the fibrillar form
induced neuronal cell death, it was thought that amyloid fibrils played the biggest role in
development of AD (Lorenzo & Yankner, 1994). However, that hypothesis was later challenged
as studies began to emerge showing that there was little to no correlation between the amount of
fibrillar β-amyloid build up and the progression of neurological deficits. Due to an increase in
evidence suggesting a direct correlation between the levels of oligomers and the progression of
AD, it is now widely thought that oligomers are the most toxic form of β-amyloid (Gong et al.,
2003).

β-amyloid Concentrations and α7 nAChR interactions
Recently studies have shown that different concentrations of β-amyloid alter the kinetics
of α7 nAChRs in different ways. While several studies have demonstrated antagonistic results at
a nanomolar (or higher) concentrations of β-amyloid, (Grassi et al., 2003; Liu, Kawai, & Berg,
2001; Pettit, Shao, & Yakel, 2001) reports of the effects of picomolar concentrations of βamyloid are not quite as consistent. Some studies report that picomolar concentration of βamyloid inhibit the activation of α7 nAChRs (Grassi et al., 2003; Lamb, Melton, & Yakel, 2005;
Pym et al., 2005), while other studies report direct activation of nAChRs by β-amyloid in the
picomolar range (Dineley, Bell, Bui, & Sweatt, 2002; Puzzo et al., 2008; Wu, Khan, & Nichols,
7

2007). When activation of α7 channels is reported, it is also unclear if activation by β-amyloid
occurs repetitively or only on the first exposure to β-amyloid. The discrepancy in these findings
could possibly be due to different forms of β-amyloid (monomers, oligomers, or fibrils), whether
the β-amyloid used is human or rodent β-amyloid, or differences between human subunit genes
and rodent subunit genes.

SPECIFIC AIMS
In this study we use human α7 subunit nAChRs expressed in Xenopus oocytes to do the
following:
1. Determine if picomolar concentrations of β-amyloid will activate α7 nAChRs. If they do then
we will establish a dose response curve. Acetylcholine will be used to activate the channels
to ensure they are working properly.
2. If no direct activation is seen then we will determine the effects of β-amyloid on the kinetics
of the channel in response to ACh. This will be done by administering two applications of
ACh for seven seconds each. Next, β-amyloid will be applied for seven seconds and the two
applications of ACh will be applied again. We will then evaluate the peak amplitude, rise
time, decay time, and decay tau, comparing the first peak pre β-amyloid and the first peak
post β-amyloid. We will evaluate the same comparisons for the second peaks.

METHODS
Plasmid DNA Preparation
Human α7 (origene# SC124074-20) subunit genes in the pCMV6-XL4 plasmid were
purchased from Origene Technologies, Rockville MD. All plasmids were transformed into
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chemically competent One Shot® e.coli cells (Invitrogen , Carlsbad CA) according to the
protocol supplied by the manufacturer. Plasmid isolation and purification were performed using
the HiSpeed® plasmid purification kit by QIAGEN Inc. (Valencia CA).
Plasmids containing α7 genes were linearized by restriction digest with SacI (New England
BioLabs). The conditions were followed according to the suggested protocol from New England
BioLabs. The mRNA was then transcribed, capped on the 5’ end, a poly(A) tail was added, and
LiCL purification was performed using the mMessage mMachine® T7 Ultra Kit (Ambion ,
Carlsbad CA) according to the protocol provided. RNA was re-suspended in TE Buffer
(Bioexpress, Layton UT), aliquoted, and stored at -80 degrees Celsius until used.

Xenopus Oocyte Isolation
Oocytes were harvested from female Xenopus laevis frogs purchased from Xenopus 1,
Inc. (Dexter MI). The frogs were housed in an environmental chamber with a 12-hour day/night
cycle with the temperature was maintained at 17-19 degrees Celsius. The frogs were fed either
beef heart or liver bi-weekly.
Surgeries were performed once a week under sterile conditions and in accordance with
the IACUC protocol. Frogs were anesthetized by submersion in a solution (12 mM NaCl, 0.134
mM KCl, 0.181 mM CaCl2, 0.476 mM NaHCO3, 5mM Hepes) containing 0.1%
ethylmetaaminobenzoate (MS-222; Sigma, St. Louis MO) adjusted to pH 7.5 with NaOH, for at
least 15 minutes and until notably unresponsive. Each frog underwent a maximum of six
surgeries with at least six weeks between each surgery. After the sixth surgery the frog was
sacrificed.
Ovary sacs were placed in a calcium free OR-2 solution ( 89.5 mM NaCl, 2mM KCl,
1mM MgCl2 anhydrous, 5mM Hepes, adjusted to pH 7.5 with NaOH) and manually separated
9

with forceps. Oocytes were then defollicuated by treatment with collagenase A (Sigma, St.
Louis MO). The oocytes were incubated for 2-2.5 hours on a tilting table at 17-19 degrees
Celsius. The cells were then rinsed and stored in an OR-2 solution with Ca2+ (82 mM NaCl, 2.5
mM KCl, 1 mM Na2HPO4, 5 mM Hepes, 1 mM CaCl, 1 mM MgCl2 anhydrous, adjusted to ph
7.5 with NaOH ) at 14-17 degrees Celsius for a minimum of 24 hours prior to injections.

RNA Expression in Xenopus Oocytes
Human α7 mRNA was injected into oocytes using a nanoject II automatic nanoliter
injector (Drummond Scientific, Broomall PA). Each oocyte was injected with 50.6 nL of mRNA
for a total concentration of 75.9 ng α7 mRNA per oocyte. The oocytes remained in a solution of
OR-2 with Ca2+ at 14-17 degrees Celsius. The solution was changed daily and recordings were
obtained 3-5 days later.

Two-electrode Voltage Clamp Electrophysiology
The kinetics of the ion channels were measured by two-electrode voltage clamp
electrophysiology using a standard Geneclamp 500B amplifier (Axon Instruments, Sunnyvale
CA) and a Digidata 1322A digitizer (Axon Instruments, Sunnyvale CA). Traces were recorded
using Clampex 9.2 software (Axon Instruments, Sunnyvale CA) and analyzed on ClampFit 9.2
(Axon Instruments, Sunnyvale CA). Electrodes containing 3 M KCl and having a resistance of 1
to 10 mΩ were made from 1.5mm borosilicate glass capillaries (Harvard Apparatus, Kent,
England) pulled on a Flaming/Brown micropipette puller model P-97 (Sutter Instrument, Novato
CA). Holding potentials were clamped at -60 mV. Traces were sampled at 5 KHz and filtered at
1000 Hz.
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Oocytes were continuously perfused with OR-2 with Ca2+ at 15-18 mL/minute. The
oocytes were stabilized on a perfusion platform (model RC-1Z Warner Instruments, Hamden
CT). Acetylcholine solutions (10 μM, 33 μM, 100 μM, 333 μM, 100 μM) were prepared fresh
each week from powdered ACh (Sigma, St. Louis MO) in OR-2 with Ca2+. Administration was
controlled by an automated perfusion system (Valvelink 8 Automate Scientific Inc., Berkley
CA). A β-amyloid scrambled peptide was used as a control to ensure that any interactions
observed were specific to the β-amyloid42 peptide. The scramble peptide is composed of the
same amino acids that make up β-amyloid42, but they are arranged in a different sequence than
the β-amyloid42 peptide.
β-amyloid42 and β-amyloid scrambled (AnaSpec Inc., Fremont CA) were prepared from
powder and were dissolved in OR2 with Ca2+ for a final concentration of 1 pM, 30 pM, 300pM,
1 nm, and 30 nm. β-amyloid dilutions were made fresh and kept at room temperature. ACh, βamyloid, and β-amyloid scrambled were applied for seven seconds. All electrophysiological
experiments were performed at room temperature.
A control valve containing OR2 with Ca2+ was used to ensure there were no perfusion
artifacts as a result of switching valves. The programs used are as follows:
The program to obtain the dose-response curve with ACh was as follows:
5 seconds OR-2 with Ca2+
7 seconds control valve OR-2 with Ca2+
10 seconds OR-2 with Ca2+
7 seconds Ach (1000 μM, 333 μM, 100 μM, 33 μM, or 10μM)
91 seconds wash with OR-2 with Ca2+
The program for paired peak perfusion of ACh was as follows:
5 seconds OR-2 with Ca2+
7 seconds ACh 333 μM
7 seconds OR-2 with Ca2+
7 seconds ACh 333 μM
91 seconds OR-2 with Ca2+
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The program for paired peak perfusion with β-amyloid and β-amyloid scramble was as follows:
5 seconds OR-2 with Ca2+
7 seconds β-amyloid or β-amyloid scramble (1 pM, 30 pM, 300 pM, 1 nM, and 30 nM)
7 seconds OR-2 with Ca2+
7 seconds ACh 333 μM
7 seconds OR-2 with Ca2+
7 seconds ACh 333 μM
80 seconds OR-2 with Ca2+
The programs included five repetitions (sweeps) of the above protocols to measure
reproducibility of the responses measured.

Data Analysis and Statistical Procedures

The acetylcholine dose-response curve was fit with a sigmoidal curve using Prism 4.0,
GraphPad software (San Diego CA). InStat ver. 3.05, GraphPad software (San Diego CA) was
used to perform repeated measures ANOVA, Tukey-Kramer post-hic testing, and two-tailed Ttest statistical analysis. The peak amplitude for each oocyte in response to a 333 μM ACh
application was used to normalize the data to a 100% response for each oocyte. Repeated
measures ANOVA analysis was used to compare the peak amplitude, rise time, decay time and
tau decay for the first paired peak pre β-amyloid with the first paired peak post β-amyloid
application. The same statistical analysis was use to compare the second paired peak pre βamyloid to the second paired peak post β-amyloid. The Tukey-Kramer post-hoc analysis was
also used to compare these categories when relevant. Statistical significance was determined by
p<0.05.
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RESULTS
Acetylcholine Dose-Response Curve
To ensure that naïve oocytes (oocytes prior to α7 mRNA injections) were not responsive to
acetylcholine applications we applied 333 μM acetylcholine to an uninjected (naïve oocyte)
(Figure 3). No response was observed. When acetylcholine is applied to an oocyte injected with
α7 mRNA, a downward peak is produced, showing activation of the α7 nAChR (Figure 4).

Naïve Oocyte

Figure 3 A control valve with OR-2 shows that there are no artifacts resulting
from changing profusion valves. A naïve oocyte shows no response when
333 μM acetylcholine is applied.

333 μM Acetylcholine

Figure 4 An oocyte injected with α7 mRNA demonstrates a response to 333 μM
acetylcholine.
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Acetylcholine was applied to oocytes expressing α7 nAChRs for seven seconds at
concentrations of 1000 μM, 333 μM, 100 μM, 33 μM, or 10μM. Data was collected at each
concentration with five sweeps of the acetylcholine application program. All data points were
normalized to the average peak response of the 333 μM ACh concentration. The peak amplitudes
were measured at each concentration and used to make a dose-response curve (Figure 5). The
EC50 obtained is 85 μM (r2 = .9378, Hill coefficient = 2.518) and fits within the previously
established range of the EC value for α7, verifying that the expression of α7 nAChRs display
normal characteristics for this subtype configuration (Briggs & McKenna, 1996; Houlihan et al.,
2001; Papke, Dwoskin, & Crooks, 2007).

Figure 5 Acetylcholine dose-response curve on α7 nAChRs, using
acetylcholine concentrations of 1000 μM, 333 μM, 100 μM, 33
μM, and 10μM. The EC50 = 85 μM.

14

Picomolar Concentrations of β-amyloid on α7 nAChRs
Occasionally, when changing the valves applying solutions, a pressure artifact would
occur. To test for these pressure artifacts, a control program was run on each oocyte where OR-2
solution was applied, then the valve was switched to a different valve that still administered OR2. Any changes resulting from a valve switch could then be detected.
Oocytes were perfused with β-amyloid for seven seconds at 1 pM, 30 pM, 300 pM, 1,000
pM, and 30,000 pM, after which acetylcholine was applied for seven seconds. The test
application of β-amyloid was followed by two applications of acetylcholine to ensure that the α7
nAChRs were responsive to a known agonist. Data was collected for five sweeps of the program
at each concentration. None of the concentrations of β-amyloid showed significant activation of
α7 nAChRs, therefore no dose-response curve for β-amyloid was obtainable. Figure 6 shows the
lowest concentration of β-amyloid (1 pM) and figure 7 shows the highest concentration of βamyloid (30,000 pM).

1 pM β-amyloid

Figure 6 Application of 1 pM β-amyloid elicits no response on α7 nAChRs. The
oocyte was responsive to acetylcholine, indicating that the α7 nAChRs
were functioning properly.
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30,000 pM β-amyloid

Figure 7 Application of 30,000 pM β-amyloid elicits no response on α7 nAChRs.
The oocyte was responsive to acetylcholine, indicating that the α7
nAChRs were functioning properly.

Seven-second Wash of β-amyloid
Since no activating effects were observed with β-amyloid by itself, we wanted to see if βamyloid would alter the activation or desensitization kinetics of the α7 ion channels in response
to activation by the normal ligand, ACh. We first ran five sweeps of a paired peak program in
which 2 doses of acetylcholine were administered seven seconds apart. Then we ran five sweeps
of the β-amyloid program, which administered β-amyloid for seven seconds, washed the oocyte
for 7 seconds with OR-2, then applied two seven-second applications of acetylcholine. The peak
amplitudes, rise times, decay times, and decay taus were compared between the first paired peak
before β-amyloid was applied and the first paired peak after application. The same comparisons
were made on the second paired peak pre β-amyloid application to the second paired peak post
β-amyloid application (Table 1). A fresh oocyte was used at each concentration and data was
collected for five sweeps of each program.
At 30 pM β-amyloid, the peak amplitudes of the first peaks were decreased by
approximately 25 percent (Figure 8). At 300 pM β-amyloid, the peak amplitudes of the first
16

peaks were increased (Figure 9). All other concentrations showed no relative changes in peak
amplitude when comparing the first peaks.

30 pM β-amyloid

Figure 8 Two seven-second applications of 333 µM acetylcholine result in
downward peaks (black trace). A seven second application of 30 pM βamyloid was applied to the oocyte, followed by a seven-second wash
with OR-2, and then two seven second applications of 333 µM
acetylcholine. The two seven-second applications of 333 µM
acetylcholine applied after the β-amyloid (red trace) show a decrease in
peak amplitude by approximately 25%.

300 pM β-amyloid

Figure 9 Two seven-second applications of 333 µM acetylcholine result in
downward peaks (black trace). A seven second application of 300 pM βamyloid was applied to the oocyte, followed by a seven-second wash
with OR-2, and then two seven second applications of 333 µM
acetylcholine. The two seven-second applications of 333 µM
acetylcholine applied after the β-amyloid (red trace) show an increase
in peak amplitude.
17

Table 1 Summary table of statistical analysis using a repeated measures ANOVA.
Peak amplitude, rise time, decay time, and decay tau were calculated
comparing the first peak pre β-amyloid to the first peak post β-amyloid
application. The second peak pre β-amyloid compared to the second peak
post β-amyloid application was also evaluated.
* T-test used to calculate
the P value.

Long wash of β-amyloid
Since variable inhibiting effects on acetylcholine induced peaks were observed on α7
nAChRs when β-amyloid was applied for seven seconds, we tried increasing the wash times to
see if a longer application of β-amyloid in the picomolar range would cause any effects. Five
sweeps of a normal application of 300 µM acetylcholine was applied to determine the baseline
maximal ACh response, the oocyte was then washed with β-amyloid for 2-5 minutes, and
another application of acetylcholine was applied. The post β-amyloid wash application of
18

acetylcholine was administered five times, with a wash time of 2 mins with OR-2 with Ca2+
between each application. At 30,000 pM β-amyloid there appears to be inhibition of the peak
amplitude, with recovery occurring after each wash with OR-2 with Ca2+ (Figure 11). However,
at all other concentrations, no significant inhibition is observed. A β-amyloid scrambled peptide
was used as a control to ensure that any interactions observed were specific to the β-amyloid42
peptide (Figure 10).

30,000 pM β-amyloid vs 30,000 β-amyloid Scramble

Figure 10 The top two charts show the percent block of peak amplitude after
30,000 pM β-amyloid is applied for five minutes. During each sweep a
seven-second application of 333 µM acetylcholine is administered,
followed by 2 minutes of washing with OR-2. The lower two charts
show the same experiment using 30,000 pM (30 nM) β-amyloid
scramble peptide instead of β-amyloid.
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Percent block of Peak Amplitude when β-amyloid is applied for 2-5 minutes

Figure 11 The pre wash is the peak amplitude for the average of five
acetylcholine activated peaks. Then β-amyloid was applied (three
minutes for 1,000 pM, all other concentrations β-amyloid was applied
for five minutes). Sweep one was measured right after β-amyloid
application. During each sweep a seven-second application of 333 µM
acetylcholine is administered, followed by 2 minutes of washing with
OR-2. Two minutes of washing with OR-2 occurred between each
successive sweep. Application of 30,000 pM β-amyloid blocks the peak
amplitude, which washes out over time, with complete recovery of the
peak amplitude after six minutes of washing.
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Percent Block of Peak Amplitude by β-amyloid
% Block Of Peak 1 on First Wash
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Figure 12 Applications of 30,000 and 300 pM β-amyloid, for five
minutes, are the only concentrations that show inhibition of
the peak amplitude when acetylcholine is administered.

DISCUSSION
While several studies have demonstrated antagonistic results (block of peak current for a7
nAChRs) at a nanomolar (or higher) concentration of β-amyloid, the effects of picomolar
concentrations are not quite as consistent. Some studies report that picomolar concentrations of
β-amyloid inhibit the activation of α7 nAChRs, while other studies report direct activation of
nAChRs by β-amyloid alone. The estimated normal levels of endogenously produced β-amyloid
are in the picomolar range (Cirrito et al., 2003), while those of Alzheimer’s patients are much
higher. Understanding the interactions between β-amyloid and nAChRs at picomolar
concentrations versus nanomolar (or higher) concentrations can help us better understand the
differences in functioning that occur between normal individuals and Alzheimer’s patients.
In this study we show that picomolar concentrations (1 pM, 30 pM, 300 pM, 1,000 pM,
and 30,000 pM) of β-amyloid do not directly activate human α7 nAChRs. This is contrary to a
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previous study by Dineley et. al. which reported that picomolar concentrations of β-amyloid
activated α7 nAChRs. The discrepancy in these findings could be a result of several different
factors.
Three different confirmations of β-amyloid exist: monomers, oligomers, and fibrils. The
conditions under which β-amyloid is prepared and stored affect the form it takes. It is possible
that the different confirmations will interact with the α7 nAChRs differently. In our study we
prepared the β-amyloid fresh from powder by mixing it with OR-2 solution. One of the ways to
change from monomers to oligomers is to let the β-amyloid incubate for a few hours. Since our
experiments started early in the morning and lasted until the evening, we wanted to rule out the
possibility of the β-amyloid clustering with time and taking on a different form. Thus, possibly
interacting with the α7 nAChRs differently. To ensure that the interactions remained consistent
through out the day, we ran the same experiment (same protocol and same concentration of βamyloid) at the beginning of the day and at the end of the day. We then compared the peak
amplitude, rise time, and decay time. No statistical differences were observed between the two
experiments. We weren’t able to characterize which confirmation was most predominant, but we
were able to rule out the possibility of the interaction of β-amyloid changing through out the day.
Some other differences in β-amyloid types are human versus rat, or the length of the
peptide sequence. In our experiments we used human β-amyloid, 42 amino acids long.
Differences could also be produced depending on the species of the α7receptors used, rat versus
human. We used human α7 mRNA, Dineley et al. used rat α7 mRNA. In addition, the
application time of β-amyloid could produce different results.
We demonstrated that at a seven-second application of β-amyloid, 30 pM will inhibit the
peak amplitude of an ACh induced response and 300 pM will increase the peak amplitude of α7
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nAChRs. However, at a longer (five minute) application of β-amyloid, 300 pM slightly inhibited
the peak amplitude. Inhibition is also seen at the 30,000 pM concentration. This inhibition
washes out with time, with full recovery occurring at six to eight minutes of wash time at 15-18
mL/minute.
At picomolar concentrations of β-amyloid, we do observe interactions with the α7
nAChRs that significantly alter the kinetics of the channels when they are activated by the
endogenous ligand, ACh. However the exact pattern of the interactions remains unclear at this
time since some concentrations showed an increase in current and other concentrations showed a
decrease. More experiments will have to be preformed to more fully characterize the interactions
that occur. As an example, performing the seven-second application of β-amyloid followed
directly by an application of acetylcholine, instead of administering a seven-second wash
between the two, may provide more clear data. Or perhaps co-application of β-amyloid with ACh
would provide more consistent findings. Our profusion rate of 15-18 mL/minute is rather fast
compared to previous reports and could account for some of the differences we observed in our
experiments compared to those already published, since the higher perfusion would be expected
to wash off any ligands more quickly, perhaps minimizing the effects seen.
Also, we’d like to repeat the experiments where we used a five-minute application of βamyloid in order to obtain enough data points so that statistical analysis can be performed.
Repeating this experiment will also help us to better evaluate the wash out times and how
quickly we are able to see recovery.
This data is clinically relevant to the human population because the endogenous levels in
a healthy individual of β-amyloid are estimated to be in the picomolar range. During the disease
state of Alzheimer’s Disease these levels increase into the nanomolar or higher range. At these
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higher concentrations, it has been shown that β-amyloid inhibits activation of α7 nAChRs.
Understanding how the nAChRs interact with β-amyloid at normal levels will help us to better
understand the change in functioning that occurs in the brain between a healthy individual and an
individual with Alzheimer’s disease. A more clear understanding of the changes that occur in the
development of Alzheimer’s disease will help us to better know what types of treatments to
investigate.
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